For each medicine in our trial, approval and spending data that ChEMBL has a record for: which protein it acts on and how, with every other medicine that shares the target.
1,662 medicines in our registers are matched to a ChEMBL record, and 1,078 of them have a recorded mechanism of action naming the protein they act on. EGFR (epidermal growth factor receptor) is the most common single target, with 23 medicines. Each target below links to a page listing every medicine that acts on it, and each medicine links to its trials, approvals and spending. Every link is checked against a second, independent source, the IUPHAR/BPS Guide to PHARMACOLOGY: 831 of 1,361 links appear in both, and each target page says which source lists each medicine. Medicines that act on a family of proteins, such as tubulin, are shown on the medicine's own page rather than here.
| Target | Medicines | In both sources | Most common action | Examples with pages here |
|---|---|---|---|---|
| EGFR Epidermal growth factor receptor |
23 | 21 | Inhibitor | Afatinib, Amivantamab, Brigatinib, Cetuximab |
| KDR Kinase insert domain receptor |
21 | 17 | Inhibitor | Axitinib, Cabozantinib, Cabozantinib S-malate, Famitinib |
| PDCD1 Programmed cell death 1 |
21 | 16 | Inhibitor | Balstilimab, Budigalimab, Cadonilimab, Camrelizumab |
| DRD2 Dopamine receptor D2 |
18 | 15 | Antagonist | Aripiprazole, Brexpiprazole, Cabergoline, Cariprazine |
| OPRM1 Opioid receptor mu 1 |
18 | 13 | Agonist | Alfentanil, Buprenorphine, Dezocine, Fentanyl |
| NR3C1 Nuclear receptor subfamily 3 group C member 1 |
17 | 14 | Agonist | Betamethasone, Budesonide, Clobetasol Propionate, Cortisone |
| FLT4 Fms related receptor tyrosine kinase 4 |
16 | 9 | Inhibitor | Axitinib, Famitinib, Fruquintinib, Lenvatinib |
| KIT KIT proto-oncogene, receptor tyrosine kinase |
16 | 8 | Inhibitor | Avapritinib, Famitinib, Imatinib, Masitinib |
| PTGS2 Prostaglandin-endoperoxide synthase 2 |
16 | 11 | Inhibitor | Acetaminophen, Aspirin, Celecoxib, Diclofenac |
| ERBB2 Erb-b2 receptor tyrosine kinase 2 |
15 | 9 | Inhibitor | Afatinib, Dacomitinib, Disitamab Vedotin, Lapatinib |
| FLT1 Fms related receptor tyrosine kinase 1 |
15 | 5 | Inhibitor | Axitinib, Famitinib, Fruquintinib, Lenvatinib |
| PDGFRB Platelet derived growth factor receptor beta |
15 | 8 | Inhibitor | Famitinib, Imatinib, Masitinib, Midostaurin |
| SCN4A Sodium voltage-gated channel alpha subunit 4 |
15 | 2 | Blocker | Bupivacaine, Carbamazepine, Cenobamate, Lacosamide |
| ADRB1 Adrenoceptor beta 1 |
14 | 11 | Antagonist | Bisoprolol, Carvedilol, Dobutamine, Dopamine |
| HTR2A 5-hydroxytryptamine receptor 2A |
14 | 10 | Antagonist | Aripiprazole, Brexpiprazole, Clozapine, Haloperidol |
| SCN5A Sodium voltage-gated channel alpha subunit 5 |
14 | 2 | Blocker | Carbamazepine, Cenobamate, Flecainide, Lacosamide |
| SLC6A4 Solute carrier family 6 member 4 |
14 | 12 | Inhibitor | Amitriptyline, Citalopram, Desvenlafaxine, Duloxetine |
| ADRB2 Adrenoceptor beta 2 |
13 | 12 | Agonist | Carvedilol, Dobutamine, Ephedrine, Epinephrine |
| PDGFRA Platelet derived growth factor receptor alpha |
13 | 4 | Inhibitor | Avapritinib, Famitinib, Masitinib, Midostaurin |
| JAK1 Janus kinase 1 |
12 | 11 | Inhibitor | Abrocitinib, Baricitinib, Brepocitinib, Delgocitinib |
| SLC6A2 Solute carrier family 6 member 2 |
12 | 8 | Inhibitor | Amitriptyline, Atomoxetine, Bupropion, Desvenlafaxine |
| AR Androgen receptor |
10 | 6 | Antagonist | Apalutamide, Bicalutamide, Darolutamide, Enzalutamide |
| BTK Bruton tyrosine kinase |
10 | 9 | Inhibitor | Acalabrutinib, Fenebrutinib, Ibrutinib, Orelabrutinib |
| CD3E CD3 epsilon subunit of T-cell receptor complex |
10 | 5 | Binding agent | Blinatumomab, Elranatamab, Epcoritamab, Glofitamab |
| HRH1 Histamine receptor H1 |
10 | 8 | Antagonist | Cetirizine Hydrochloride, Chlorpheniramine, Desloratadine, Diphenhydramine |
| JAK2 Janus kinase 2 |
10 | 9 | Inhibitor | Baricitinib, Delgocitinib, Fedratinib, Filgotinib |
| ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase |
9 | 7 | Inhibitor | Asciminib, Bosutinib, Dasatinib, Imatinib |
| ADRA1A Adrenoceptor alpha 1A |
9 | 7 | Agonist | Carvedilol, Ephedrine, Epinephrine, Labetalol |
| ADRB3 Adrenoceptor beta 3 |
9 | 7 | Agonist | Carvedilol, Ephedrine, Epinephrine, Isoproterenol |
| CD19 CD19 molecule |
9 | 4 | Binding agent | Axicabtagene Ciloleucel, Blinatumomab, Inebilizumab, Lisocabtagene maraleucel |
| CD274 CD274 molecule |
9 | 0 | Inhibitor | Adebrelimab, Atezolizumab, Avelumab, Bintrafusp alfa |
| FGFR1 Fibroblast growth factor receptor 1 |
9 | 8 | Inhibitor | Erdafitinib, Fexagratinib, Futibatinib, Infigratinib |
| FLT3 Fms related receptor tyrosine kinase 3 |
9 | 6 | Inhibitor | Famitinib, Fedratinib, Gilteritinib, Midostaurin |
| MS4A1 Membrane spanning 4-domains A1 |
9 | 9 | Binding agent | Epcoritamab, Glofitamab, Mosunetuzumab, Obinutuzumab |
| PIK3CD Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
9 | 6 | Inhibitor | Copanlisib Hydrochloride, Duvelisib, Gedatolisib, Idelalisib |
| RET Ret proto-oncogene |
9 | 6 | Inhibitor | Alectinib, Pralsetinib, Quizartinib, Regorafenib |
| TOP2A DNA topoisomerase II alpha |
9 | 4 | Inhibitor | Amrubicin, Daunorubicin, Dexrazoxane, Doxorubicin |
| BRAF B-Raf proto-oncogene, serine/threonine kinase |
8 | 7 | Inhibitor | Belvarafenib, Dabrafenib, Encorafenib, Naporafenib |
| C5 Complement C5 |
8 | 0 | Inhibitor | Avacincaptad Pegol, Cemdisiran, Crovalimab, Eculizumab |
| ESR1 Estrogen receptor 1 |
8 | 6 | Degrader | Camizestrant, Elacestrant, Estradiol, Estradiol valerate |
| FGFR3 Fibroblast growth factor receptor 3 |
8 | 6 | Inhibitor | Erdafitinib, Fexagratinib, Futibatinib, Infigratinib |
| INSR Insulin receptor |
8 | 2 | Agonist | Insulin aspart, Insulin Degludec, Insulin glargine, Insulin icodec |
| MET MET proto-oncogene, receptor tyrosine kinase |
8 | 7 | Inhibitor | Amivantamab, Cabozantinib, Cabozantinib S-malate, Capmatinib |
| PARP1 Poly(ADP-ribose) polymerase 1 |
8 | 5 | Inhibitor | Niraparib, Olaparib, Pamiparib, Rucaparib |
| PDE3A Phosphodiesterase 3A |
8 | 3 | Inhibitor | Aminophylline, Anagrelide, Cilostazol, Dipyridamole |
| AGTR1 Angiotensin II receptor type 1 |
7 | 7 | Antagonist | Angiotensin II, Candesartan, Irbesartan, Losartan |
| ALK ALK receptor tyrosine kinase |
7 | 6 | Inhibitor | Alectinib, Brigatinib, Ceritinib, Crizotinib |
| CHRM3 Cholinergic receptor muscarinic 3 |
7 | 6 | Antagonist | Atropine, Oxybutynin, Solifenacin, Tolterodine |
| CSF1R Colony stimulating factor 1 receptor |
7 | 4 | Inhibitor | Axatilimab, Emactuzumab, Pazopanib, Quizartinib |
| DRD3 Dopamine receptor D3 |
7 | 3 | Agonist | Cariprazine, Haloperidol, Levodopa, Olanzapine |
| FGFR2 Fibroblast growth factor receptor 2 |
7 | 6 | Inhibitor | Erdafitinib, Fexagratinib, Futibatinib, Infigratinib |
| GLP1R Glucagon like peptide 1 receptor |
7 | 6 | Agonist | Dulaglutide, Exenatide, Liraglutide, Retatrutide |
| MAP2K1 Mitogen-activated protein kinase kinase 1 |
7 | 6 | Inhibitor | Avutometinib, Binimetinib, Cobimetinib, Mirdametinib |
| MAP2K2 Mitogen-activated protein kinase kinase 2 |
7 | 3 | Inhibitor | Avutometinib, Binimetinib, Cobimetinib, Mirdametinib |
| NR3C2 Nuclear receptor subfamily 3 group C member 2 |
7 | 6 | Antagonist | Drospirenone, Eplerenone, Finerenone, Fludrocortisone |
| PARP2 Poly(ADP-ribose) polymerase 2 |
7 | 4 | Inhibitor | Niraparib, Olaparib, Pamiparib, Rucaparib |
| PDE3B Phosphodiesterase 3B |
7 | 0 | Inhibitor | Aminophylline, Anagrelide, Dipyridamole, Levosimendan |
| PGR Progesterone receptor |
7 | 5 | Agonist | Drospirenone, Dydrogesterone, Levonorgestrel, Medroxyprogesterone Acetate |
| PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
7 | 7 | Inhibitor | Alpelisib, Copanlisib Hydrochloride, Gedatolisib, Inavolisib |
| TYK2 Tyrosine kinase 2 |
7 | 7 | Inhibitor | Brepocitinib, Delgocitinib, Deucravacitinib, Filgotinib |
| CHRM2 Cholinergic receptor muscarinic 2 |
6 | 5 | Antagonist | Atropine, Oxybutynin, Solifenacin, Tolterodine |
| F8 Coagulation factor VIII |
6 | 0 | Exogenous protein | Damoctocog alfa pegol, Efanesoctocog alfa, Susoctocog Alfa, Turoctocog alfa pegol |
| GNRHR Gonadotropin releasing hormone receptor |
6 | 6 | Agonist | Buserelin, Degarelix, Goserelin, Histrelin |
| JAK3 Janus kinase 3 |
6 | 6 | Inhibitor | Delgocitinib, Filgotinib, Ritlecitinib, Ruxolitinib |
| MTOR Mechanistic target of rapamycin kinase |
6 | 4 | Inhibitor | Gedatolisib, Samotolisib, Sapanisertib, Vistusertib |
| NTRK1 Neurotrophic receptor tyrosine kinase 1 |
6 | 3 | Inhibitor | Cenegermin, Entrectinib, Larotrectinib, Regorafenib |
| OPRK1 Opioid receptor kappa 1 |
6 | 4 | Agonist | Buprenorphine, Dezocine, Nalbuphine, Naloxone Hydrochloride |
| PCSK9 Proprotein convertase subtilisin/kexin type 9 |
6 | 4 | Inhibitor | Alirocumab, Evolocumab, Inclisiran, Lerodalcibep |
| S1PR1 Sphingosine-1-phosphate receptor 1 |
6 | 6 | Agonist | Cenerimod, Etrasimod, Fingolimod, Ozanimod |
| SLC5A2 Solute carrier family 5 member 2 |
6 | 5 | Inhibitor | Canagliflozin, Dapagliflozin, Ertugliflozin, Henagliflozin |
| TOP1 DNA topoisomerase I |
6 | 1 | Inhibitor | Irinotecan, Patritumab deruxtecan, Sacituzumab Govitecan, Topotecan |
| TYMS Thymidylate synthetase |
6 | 3 | Inhibitor | Capecitabine, Floxuridine, Fluorouracil, Pemetrexed |
| ADORA3 Adenosine A3 receptor |
5 | 4 | Antagonist | Adenosine, Aminophylline, Caffeine, Namodenoson |
| CTLA4 Cytotoxic T-lymphocyte associated protein 4 |
5 | 3 | Inhibitor | Cadonilimab, Ipilimumab, Tremelimumab, Zalifrelimab |
| EDNRA Endothelin receptor type A |
5 | 5 | Antagonist | Ambrisentan, Atrasentan, Bosentan, Macitentan |
| FKBP1A FKBP prolyl isomerase 1A |
5 | 3 | Inhibitor | Everolimus, Pimecrolimus, Sirolimus, Tacrolimus |
| GRIN2A Glutamate ionotropic receptor NMDA type subunit 2A |
5 | 2 | Negative allosteric modulator | Amantadine, Dextromethorphan, Esketamine, Ketamine |
| HDAC1 Histone deacetylase 1 |
5 | 4 | Inhibitor | Abexinostat, Belinostat, Entinostat, Vorinostat |
| HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase |
5 | 5 | Inhibitor | Atorvastatin, Pitavastatin, Pravastatin, Rosuvastatin |
| HTR1A 5-hydroxytryptamine receptor 1A |
5 | 4 | Partial agonist | Aripiprazole, Brexpiprazole, Buspirone, Ulotaront |
| HTR2C 5-hydroxytryptamine receptor 2C |
5 | 4 | Antagonist | Mirtazapine, Olanzapine, Quetiapine, Risperidone |
| IL17A Interleukin 17A |
5 | 0 | Inhibitor | Bimekizumab, Ixekizumab, Secukinumab, Vunakizumab |
| MPL MPL proto-oncogene, thrombopoietin receptor |
5 | 5 | Agonist | Avatrombopag, Eltrombopag, Hetrombopag, Lusutrombopag |
| NTRK2 Neurotrophic receptor tyrosine kinase 2 |
5 | 2 | Inhibitor | Cenegermin, Entrectinib, Larotrectinib, Repotrectinib |
| NTRK3 Neurotrophic receptor tyrosine kinase 3 |
5 | 2 | Inhibitor | Cenegermin, Entrectinib, Larotrectinib, Repotrectinib |
| PPARA Peroxisome proliferator activated receptor alpha |
5 | 4 | Agonist | Chiglitazar, Elafibranor, Fenofibrate, Pemafibrate |
| RAF1 Raf-1 proto-oncogene, serine/threonine kinase |
5 | 3 | Inhibitor | Belvarafenib, Naporafenib, Regorafenib, Sorafenib |
| ROS1 ROS proto-oncogene 1, receptor tyrosine kinase |
5 | 2 | Inhibitor | Crizotinib, Entrectinib, Repotrectinib, Taletrectinib |
| S1PR5 Sphingosine-1-phosphate receptor 5 |
5 | 3 | Modulator | Etrasimod, Fingolimod, Ozanimod, Ponesimod |
| SERPINC1 Serpin family C member 1 |
5 | 2 | Activator | Dalteparin, Fitusiran, Heparin, Enoxaparin |
| SLC6A3 Solute carrier family 6 member 3 |
5 | 3 | Inhibitor | Bupropion, Lisdexamfetamine, Methylphenidate, Midomafetamine HCl |
| TNF Tumor necrosis factor |
5 | 0 | Inhibitor | Adalimumab, Certolizumab Pegol, Etanercept, Golimumab |
| VEGFA Vascular endothelial growth factor A |
5 | 0 | Inhibitor | Aflibercept, Bevacizumab, Conbercept, Faricimab |
| ACHE Acetylcholinesterase (Yt blood group) |
4 | 4 | Inhibitor | Donepezil, Galantamine, Huperzine A, Neostigmine |
| AVPR2 Arginine vasopressin receptor 2 |
4 | 3 | Agonist | Desmopressin, Terlipressin, Tolvaptan, Vasopressin |
| CACNA1B Calcium voltage-gated channel subunit alpha1 B |
4 | 1 | Modulator | Gabapentin, Levetiracetam, Pregabalin, Ziconotide |
| CALCRL Calcitonin receptor like receptor |
4 | 4 | Antagonist | Atogepant, Rimegepant, Ubrogepant, Erenumab |
| CD38 CD38 molecule |
4 | 4 | Inhibitor | Daratumumab, Felzartamab, Isatuximab, Mezagitamab |
| CDK4 Cyclin dependent kinase 4 |
4 | 4 | Inhibitor | Abemaciclib, Palbociclib, Ribociclib, Trilaciclib |
| CDK6 Cyclin dependent kinase 6 |
4 | 3 | Inhibitor | Abemaciclib, Palbociclib, Ribociclib, Trilaciclib |
| CHRM1 Cholinergic receptor muscarinic 1 |
4 | 2 | Antagonist | Atropine, Glycopyrronium, Amitriptyline, Oxybutynin |
| DRD4 Dopamine receptor D4 |
4 | 1 | Inverse agonist | Haloperidol, Olanzapine, Pramipexole, Dopamine |
| ERBB4 Erb-b2 receptor tyrosine kinase 4 |
4 | 1 | Inhibitor | Afatinib, Dacomitinib, Neratinib, Vandetanib |
| F10 Coagulation factor X |
4 | 4 | Inhibitor | Apixaban, Edoxaban, Emicizumab, Rivaroxaban |
| HDAC2 Histone deacetylase 2 |
4 | 3 | Inhibitor | Abexinostat, Belinostat, Entinostat, Vorinostat |
| HDAC3 Histone deacetylase 3 |
4 | 4 | Inhibitor | Abexinostat, Belinostat, Entinostat, Vorinostat |
| HDAC6 Histone deacetylase 6 |
4 | 2 | Inhibitor | Abexinostat, Belinostat, Entinostat, Vorinostat |
| HTR3A 5-hydroxytryptamine receptor 3A |
4 | 4 | Antagonist | Metoclopramide, Ondansetron, Palonosetron hydrochloride, Vortioxetine |
| IDH1 Isocitrate dehydrogenase (NADP(+)) 1 |
4 | 4 | Inhibitor | Ivosidenib, Olutasidenib, Safusidenib, Vorasidenib |
| KCNK3 Potassium two pore domain channel subfamily K member 3 |
4 | 1 | Opener | Desflurane, Doxapram, Isoflurane, Sevoflurane |
| KCNK9 Potassium two pore domain channel subfamily K member 9 |
4 | 0 | Opener | Desflurane, Doxapram, Isoflurane, Sevoflurane |
| P2RY12 Purinergic receptor P2Y12 |
4 | 2 | Antagonist | Cangrelor, Clopidogrel, Prasugrel, Ticagrelor |
| PDE5A Phosphodiesterase 5A |
4 | 2 | Inhibitor | Dipyridamole, Pentoxifylline, Sildenafil, Tadalafil |
| PIK3CG Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
4 | 2 | Inhibitor | Duvelisib, Gedatolisib, Paxalisib, Samotolisib |
| PPARG Peroxisome proliferator activated receptor gamma |
4 | 4 | Agonist | Chiglitazar, Mesalamine, Pioglitazone, Saroglitazar Magnesium |
| SSTR2 Somatostatin receptor 2 |
4 | 2 | Agonist | Lanreotide, Octreotide, Somatostatin, Lutetium Lu 177 Dotatate |
| SSTR5 Somatostatin receptor 5 |
4 | 2 | Agonist | Lanreotide, Octreotide, Somatostatin, Lutetium Lu 177 Dotatate |
| TNFRSF17 TNF receptor superfamily member 17 |
4 | 1 | Binding agent | Belantamab mafodotin, Elranatamab, Idecabtagene vicleucel, Teclistamab |
| TTR Transthyretin |
4 | 1 | Rnai inhibitor | Acoramidis, Eplontersen, Vutrisiran, Patisiran |
| ACE Angiotensin I converting enzyme |
3 | 3 | Inhibitor | Captopril, Enalapril, Ramipril |
| APP Amyloid beta precursor protein |
3 | 0 | Disrupting agent | Donanemab, Lecanemab, Aducanumab |
| ATR ATR checkpoint kinase |
3 | 3 | Inhibitor | Berzosertib, Ceralasertib, Elimusertib |
| BCL2 BCL2 apoptosis regulator |
3 | 2 | Inhibitor | Navitoclax, Venetoclax, Lisaftoclax |
| CHRM4 Cholinergic receptor muscarinic 4 |
3 | 1 | Antagonist | Glycopyrronium, Amitriptyline, Atropine |
| CHRM5 Cholinergic receptor muscarinic 5 |
3 | 1 | Antagonist | Glycopyrronium, Amitriptyline, Atropine |
| CNR1 Cannabinoid receptor 1 |
3 | 3 | Agonist | Cannabidiol, Dronabinol, Nabilone |
| CSF3R Colony stimulating factor 3 receptor |
3 | 1 | Agonist | Efbemalenograstim alfa, Filgrastim, Pegfilgrastim |
| CYP19A1 Cytochrome P450 family 19 subfamily A member 1 |
3 | 3 | Inhibitor | Anastrozole, Exemestane, Letrozole |
| DHFR Dihydrofolate reductase |
3 | 3 | Inhibitor | Methotrexate, Pemetrexed, Pralatrexate |
| DHODH Dihydroorotate dehydrogenase (quinone) |
3 | 3 | Inhibitor | Leflunomide, Teriflunomide, IMU-838 |
| DPP4 Dipeptidyl peptidase 4 |
3 | 3 | Inhibitor | Linagliptin, Sitagliptin, Vildagliptin |
| F2 Coagulation factor II, thrombin |
3 | 2 | Inhibitor | Bivalirudin, Dabigatran, Dabigatran Etexilate |
| F9 Coagulation factor IX |
3 | 1 | Exogenous protein | Emicizumab, Nonacog beta pegol, Etranacogene Dezaparvovec |
| FCGRT Fc gamma receptor and transporter |
3 | 3 | Antagonist | Nipocalimab, Rozanolixizumab, Efgartigimod |
| FDPS Farnesyl diphosphate synthase |
3 | 2 | Inhibitor | Zoledronic Acid, Alendronate, Zoledronate |
| GCGR Glucagon receptor |
3 | 3 | Agonist | Glucagon, Retatrutide, Survodutide |
| GHR Growth hormone receptor |
3 | 2 | Agonist | Somapacitan, Somatrogon, Somatropin |
| HCRTR2 Hypocretin receptor 2 |
3 | 3 | Antagonist | Daridorexant, Lemborexant, Seltorexant |
| IFNAR1 Interferon alpha and beta receptor subunit 1 |
3 | 2 | Antagonist | Anifrolumab, Peginterferon alfa-2b, Besremi |
| IL6 Interleukin 6 |
3 | 0 | Inhibitor | Clazakizumab, Siltuximab, Ziltivekimab |
| IL6R Interleukin 6 receptor |
3 | 3 | Antagonist | Sarilumab, Satralizumab, Tocilizumab |
| KCNK10 Potassium two pore domain channel subfamily K member 10 |
3 | 0 | Opener | Desflurane, Isoflurane, Sevoflurane |
| KCNK18 Potassium two pore domain channel subfamily K member 18 |
3 | 0 | Opener | Desflurane, Isoflurane, Sevoflurane |
| KCNK2 Potassium two pore domain channel subfamily K member 2 |
3 | 1 | Opener | Desflurane, Isoflurane, Sevoflurane |
| KRAS KRas proto-oncogene, GTPase |
3 | 2 | Inhibitor | Adagrasib, Sotorasib, D-1553 |
| OXTR Oxytocin receptor |
3 | 3 | Agonist | Atosiban, Carbetocin, Oxytocin |
| PPARD Peroxisome proliferator activated receptor delta |
3 | 2 | Agonist | Chiglitazar, Elafibranor, Seladelpar |
| PTGIR Prostaglandin I2 receptor |
3 | 3 | Agonist | Iloprost, Selexipag, Treprostinil |
| ROCK2 Rho associated coiled-coil containing protein kinase 2 |
3 | 3 | Inhibitor | Belumosudil, Fasudil, Ripasudil |
| SLC10A2 Solute carrier family 10 member 2 |
3 | 2 | Inhibitor | Maralixibat, Odevixibat, Volixibat |
| SLC12A3 Solute carrier family 12 member 3 |
3 | 2 | Inhibitor | Hydrochlorothiazide, Indapamide, Metolazone |
| SMN2 Survival of motor neuron 2, centromeric |
3 | 0 | Positive modulator | Nusinersen, Risdiplam, Onasemnogene Abeparvovec |
| SMO Smoothened, frizzled class receptor |
3 | 3 | Inhibitor | Sonidegib, Taladegib, Vismodegib |
| SNAP25 Synaptosome associated protein 25 |
3 | 0 | Hydrolytic enzyme | Botulinum toxin type A, OnabotulinumtoxinA, AGN-151586 |
| SRC SRC proto-oncogene, non-receptor tyrosine kinase |
3 | 2 | Inhibitor | Bosutinib, Tirbanibulin, Vandetanib |
| TACR1 Tachykinin receptor 1 |
3 | 3 | Antagonist | Aprepitant, Fosaprepitant, Tradipitant |
| TLR7 Toll like receptor 7 |
3 | 3 | Antagonist | Enpatoran, Hydroxychloroquine, Imiquimod |
| UGCG UDP-glucose ceramide glucosyltransferase |
3 | 2 | Inhibitor | Eliglustat, Miglustat, Venglustat |
| VDR Vitamin D receptor |
3 | 1 | Agonist | Cholecalciferol, Calcipotriol, Vitamin D2 |
| ACVR1 Activin A receptor type 1 |
2 | 1 | Inhibitor | Momelotinib, Pacritinib |
| ALDH5A1 Aldehyde dehydrogenase 5 family member A1 |
2 | 0 | Inhibitor | Valproic acid, Sodium valproate |
| ALOX5 Arachidonate 5-lipoxygenase |
2 | 0 | Inhibitor | Mesalamine, Sulfasalazine |
| CA2 Carbonic anhydrase 2 |
2 | 0 | Inhibitor | Acetazolamide, Topiramate |
| CA4 Carbonic anhydrase 4 |
2 | 2 | Inhibitor | Acetazolamide, Topiramate |
| CCR5 C-C motif chemokine receptor 5 |
2 | 2 | Antagonist | Leronlimab, Maraviroc |
| CD40 CD40 molecule |
2 | 0 | Inhibitor | PG-102, ABBV-927 |
| CD40LG CD40 ligand |
2 | 0 | Antagonist | Dazodalibep, Tegoprubart |
| CD47 CD47 molecule |
2 | 2 | Inhibitor | Evorpacept, Magrolimab |
| CD80 CD80 molecule |
2 | 2 | Inhibitor | Abatacept, Belatacept |
| CD86 CD86 molecule |
2 | 2 | Inhibitor | Abatacept, Belatacept |
| CFTR CF transmembrane conductance regulator |
2 | 2 | Inhibitor | Crofelemer, Ivacaftor |
| CYP11B1 Cytochrome P450 family 11 subfamily B member 1 |
2 | 1 | Inhibitor | Mitotane, Osilodrostat |
| DNMT1 DNA methyltransferase 1 |
2 | 0 | Inhibitor | Azacitidine, Decitabine |
| DNMT3A DNA methyltransferase 3 alpha |
2 | 0 | Inhibitor | Azacitidine, Decitabine |
| EGLN1 Egl-9 family hypoxia inducible factor 1 |
2 | 1 | Inhibitor | Enarodustat, Roxadustat |
| EPHA2 EPH receptor A2 |
2 | 0 | Inhibitor | Regorafenib, Vandetanib |
| EPOR Erythropoietin receptor |
2 | 1 | Agonist | Darbepoetin Alfa, Epoetin Alfa |
| ERBB3 Erb-b2 receptor tyrosine kinase 3 |
2 | 1 | Binding agent | Patritumab deruxtecan, Vandetanib |
| ESR2 Estrogen receptor 2 |
2 | 1 | Modulator | Estriol, Fulvestrant |
| F11 Coagulation factor XI |
2 | 2 | Inhibitor | Abelacimab, Milvexian |
| FSHR Follicle stimulating hormone receptor |
2 | 0 | Agonist | Follitropin delta, Gonal-F |
| GIPR Gastric inhibitory polypeptide receptor |
2 | 2 | Agonist | Retatrutide, Tirzepatide |
| GSK3B Glycogen synthase kinase 3 beta |
2 | 1 | Inhibitor | Lithium Carbonate, Tideglusib |
| HCRTR1 Hypocretin receptor 1 |
2 | 2 | Antagonist | Daridorexant, Lemborexant |
| HTR1B 5-hydroxytryptamine receptor 1B |
2 | 0 | Partial agonist | Vortioxetine, Risperidone |
| HTR4 5-hydroxytryptamine receptor 4 |
2 | 2 | Agonist | Metoclopramide, Prucalopride |
| HTR7 5-hydroxytryptamine receptor 7 |
2 | 0 | Antagonist | Lurasidone, Vortioxetine |
| IDH2 Isocitrate dehydrogenase (NADP(+)) 2 |
2 | 2 | Inhibitor | Enasidenib, Vorasidenib |
| IGF1R Insulin like growth factor 1 receptor |
2 | 2 | Inhibitor | Linsitinib, Teprotumumab |
| IL13 Interleukin 13 |
2 | 0 | Inhibitor | Lebrikizumab, Tralokinumab |
| IL17F Interleukin 17F |
2 | 0 | Inhibitor | Bimekizumab, Sonelokimab |
| IL1B Interleukin 1 beta |
2 | 0 | Inhibitor | Lutikizumab, Canakinumab |
| IL4R Interleukin 4 receptor |
2 | 1 | Antagonist | Dupilumab, Stapokibart |
| IL5 Interleukin 5 |
2 | 0 | Inhibitor | Depemokimab, Mepolizumab |
| INHBA Inhibin subunit beta A |
2 | 0 | Inhibitor | Garetosmab, Sotatercept |
| ITK IL2 inducible T cell kinase |
2 | 0 | Inhibitor | Pazopanib, Ritlecitinib |
| KCNH2 Potassium voltage-gated channel subfamily H member 2 |
2 | 0 | Blocker | Amiodarone, Fampridine |
| KEAP1 Kelch like ECH associated protein 1 |
2 | 0 | Inhibitor | Dimethyl Fumarate, Diroximel Fumarate |
| LAG3 Lymphocyte activating 3 |
2 | 2 | Inhibitor | Fianlimab, Relatlimab |
| LEPR Leptin receptor |
2 | 0 | Agonist | Metreleptin, Mibavademab |
| LPA Lipoprotein(a) |
2 | 0 | Rnai inhibitor | Olpasiran, Pelacarsen |
| NPR2 Natriuretic peptide receptor 2 |
2 | 1 | Binding agent | Vosoritide, Navepegritide |
| ODC1 Ornithine decarboxylase 1 |
2 | 1 | Inhibitor | Eflornithine, DFMO |
| PGF Placental growth factor |
2 | 0 | Inhibitor | Aflibercept, Conbercept |
| PKLR Pyruvate kinase L/R |
2 | 2 | Activator | Etavopivat, Mitapivat |
| PLAT Plasminogen activator, tissue type |
2 | 0 | Exogenous protein | Alteplase, Tenecteplase |
| PPAT Phosphoribosyl pyrophosphate amidotransferase |
2 | 0 | Inhibitor | Azathioprine, Mercaptopurine |
| PPIA Peptidylprolyl isomerase A |
2 | 1 | Modulator | Cyclosporine, Voclosporin |
| PTH1R Parathyroid hormone 1 receptor |
2 | 1 | Agonist | Palopegteriparatide, Teriparatide |
| PTK2 Protein tyrosine kinase 2 |
2 | 0 | Inhibitor | Defactinib, IN10018 |
| S1PR4 Sphingosine-1-phosphate receptor 4 |
2 | 2 | Modulator | Etrasimod, Fingolimod |
| SLC12A1 Solute carrier family 12 member 1 |
2 | 2 | Inhibitor | Bumetanide, Furosemide |
| SLC18A2 Solute carrier family 18 member A2 |
2 | 1 | Inhibitor | Lisdexamfetamine, Valbenazine |
| SOST Sclerostin |
2 | 0 | Inhibitor | Romosozumab, Setrusumab |
| SRD5A2 Steroid 5 alpha-reductase 2 |
2 | 1 | Inhibitor | Dutasteride, Finasteride |
| SV2A Synaptic vesicle glycoprotein 2A |
2 | 2 | Modulator | Brivaracetam, Levetiracetam |
| TACSTD2 Tumor associated calcium signal transducer 2 |
2 | 2 | Binding agent | Sacituzumab Govitecan |
| TEK TEK receptor tyrosine kinase |
2 | 0 | Inhibitor | Regorafenib, Vandetanib |
| TFPI Tissue factor pathway inhibitor |
2 | 0 | Inhibitor | Concizumab, Marstacimab |
| THRB Thyroid hormone receptor beta |
2 | 2 | Agonist | Levothyroxine, Resmetirom |
| TIGIT T cell immunoreceptor with Ig and ITIM domains |
2 | 1 | Inhibitor | Domvanalimab, Tiragolumab |
| TLR9 Toll like receptor 9 |
2 | 1 | Antagonist | Hydroxychloroquine, Tilsotolimod |
| TNFSF13 TNF superfamily member 13 |
2 | 0 | Inhibitor | Atacicept, Sibeprenlimab |
| TNFSF13B TNF superfamily member 13b |
2 | 0 | Inhibitor | Atacicept, Belimumab |
| TRPM8 Transient receptor potential cation channel subfamily M member 8 |
2 | 1 | Inhibitor | Elismetrep, L-menthol |
| TRPV1 Transient receptor potential cation channel subfamily V member 1 |
2 | 1 | Opener | Acetaminophen, Capsaicin |
| WEE1 WEE1 G2 checkpoint kinase |
2 | 2 | Inhibitor | Adavosertib, Azenosertib |
| XDH Xanthine dehydrogenase |
2 | 2 | Inhibitor | Allopurinol, Febuxostat |
| ABCA1 ATP binding cassette subfamily A member 1 |
1 | 1 | Inhibitor | Probucol |
| ACLY ATP citrate lyase |
1 | 1 | Inhibitor | Bempedoic acid |
| ADAMTS13 ADAM metallopeptidase with thrombospondin type 1 motif 13 |
1 | 0 | Exogenous protein | TAK-755 |
| AHR Aryl hydrocarbon receptor |
1 | 1 | Agonist | Tapinarof |
| AKR1B1 Aldo-keto reductase family 1 member B |
1 | 0 | Inhibitor | Epalrestat |
| AMY2A Amylase alpha 2A |
1 | 1 | Inhibitor | Acarbose |
| ANGPT2 Angiopoietin 2 |
1 | 0 | Inhibitor | Faricimab |
| ANO1 Anoctamin 1 |
1 | 1 | Blocker | Crofelemer |
| APOC3 Apolipoprotein C3 |
1 | 0 | Antisense inhibitor | Olezarsen |
| AURKA Aurora kinase A |
1 | 1 | Inhibitor | Alisertib |
| AURKB Aurora kinase B |
1 | 1 | Inhibitor | Chiauranib |
| AXL AXL receptor tyrosine kinase |
1 | 1 | Inhibitor | Gilteritinib |
| BCL11A BCL11 transcription factor A |
1 | 0 | Gene editing negative modulator | Exagamglogene Autotemcel |
| BCL2L1 BCL2 like 1 |
1 | 1 | Inhibitor | Navitoclax |
| C1R Complement C1r |
1 | 0 | Inhibition | Nafamostat Mesylate |
| C3 Complement C3 |
1 | 0 | Inhibitor | Pegcetacoplan |
| C5AR1 Complement C5a receptor 1 |
1 | 1 | Antagonist | Avacopan |
| CA1 Carbonic anhydrase 1 |
1 | 1 | Inhibitor | Acetazolamide |
| CA12 Carbonic anhydrase 12 |
1 | 1 | Inhibitor | Acetazolamide |
| CA7 Carbonic anhydrase 7 |
1 | 0 | Inhibition | Acetazolamide |
| CALCR Calcitonin receptor |
1 | 1 | Agonist | Calcitonin |
| CASR Calcium sensing receptor |
1 | 1 | Agonist | Etelcalcetide |
| CCR4 C-C motif chemokine receptor 4 |
1 | 1 | Cross-linking agent | Mogamulizumab |
| CD14 CD14 molecule |
1 | 0 | Inhibitor | Atibuclimab |
| CD2 CD2 molecule |
1 | 0 | Inhibitor | Siplizumab |
| CD22 CD22 molecule |
1 | 1 | Binding agent | Inotuzumab Ozogamicin |
| CD33 CD33 molecule |
1 | 1 | Binding agent | Gemtuzumab Ozogamicin |
| CD52 CD52 molecule |
1 | 1 | Inhibitor | Alemtuzumab |
| CD70 CD70 molecule |
1 | 0 | Inhibitor | Cusatuzumab |
| CD79B CD79b molecule |
1 | 1 | Binding agent | Polatuzumab Vedotin |
| CEP290 Centrosomal protein 290 |
1 | 0 | Positive modulator | Sepofarsen |
| CETP Cholesteryl ester transfer protein |
1 | 1 | Inhibitor | Obicetrapib |
| CFB Complement factor B |
1 | 1 | Inhibitor | Iptacopan |
| CFD Complement factor D |
1 | 1 | Inhibitor | Danicopan |
| CLCN2 Chloride voltage-gated channel 2 |
1 | 1 | Opener | Lubiprostone |
| CLDN18 Claudin 18 |
1 | 1 | Binding agent | Zolbetuximab |
| CLEC4C C-type lectin domain family 4 member C |
1 | 1 | Inhibitor | Litifilimab |
| CPS1 Carbamoyl-phosphate synthase 1 |
1 | 0 | Positive allosteric modulator | Carglumic Acid |
| CRHR1 Corticotropin releasing hormone receptor 1 |
1 | 1 | Antagonist | Crinecerfont |
| CSF2 Colony stimulating factor 2 |
1 | 0 | Antagonist | Plonmarlimab |
| CXCR4 C-X-C motif chemokine receptor 4 |
1 | 1 | Antagonist | Motixafortide |
| CYP11A1 Cytochrome P450 family 11 subfamily A member 1 |
1 | 1 | Inhibitor | Mitotane |
| CYP17A1 Cytochrome P450 family 17 subfamily A member 1 |
1 | 0 | Inhibitor | Abiraterone acetate |
| CYSLTR1 Cysteinyl leukotriene receptor 1 |
1 | 1 | Antagonist | Montelukast |
| DDR2 Discoidin domain receptor tyrosine kinase 2 |
1 | 0 | Inhibitor | Regorafenib |
| DLL3 Delta like canonical Notch ligand 3 |
1 | 0 | Binding agent | Tarlatamab |
| DMD Dystrophin |
1 | 0 | Positive modulator | Eteplirsen |
| DRD1 Dopamine receptor D1 |
1 | 0 | Full agonist | Dopamine |
| DRD5 Dopamine receptor D5 |
1 | 0 | Full agonist | Dopamine |
| EEF2 Eukaryotic translation elongation factor 2 |
1 | 0 | Inhibitor | Tagraxofusp |
| ELANE Elastase, neutrophil expressed |
1 | 0 | Inhibition | Sivelestat sodium |
| EPAS1 Endothelial PAS domain protein 1 |
1 | 1 | Inhibitor | Belzutifan |
| EPCAM Epithelial cell adhesion molecule |
1 | 0 | Inhibitor | MT-201 |
| EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit |
1 | 1 | Inhibitor | Tazemetostat |
| F3 Coagulation factor III, tissue factor |
1 | 1 | Binding agent | Tisotumab Vedotin |
| FAAH Fatty acid amide hydrolase |
1 | 0 | Inhibitor | Acetaminophen |
| FCGR2B Fc gamma receptor IIb |
1 | 1 | Inhibitor | Obexelimab |
| FGF23 Fibroblast growth factor 23 |
1 | 0 | Inhibitor | Burosumab |
| FN1 Fibronectin 1 |
1 | 0 | Binding agent | L19IL2 |
| FOLH1 Folate hydrolase 1 |
1 | 0 | Binding agent | Lutetium Lu-177 vipivotide tetraxetan |
| FOLR1 Folate receptor alpha |
1 | 1 | Binding agent | Mirvetuximab Soravtansine |
| FRK Fyn related Src family tyrosine kinase |
1 | 0 | Inhibitor | Regorafenib |
| GART Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase |
1 | 1 | Inhibitor | Pemetrexed |
| GLA Galactosidase alpha |
1 | 0 | Stabiliser | Migalastat HCl |
| GLP2R Glucagon like peptide 2 receptor |
1 | 1 | Agonist | Teduglutide |
| GPD2 Glycerol-3-phosphate dehydrogenase 2 |
1 | 0 | Inhibitor | Metformin |
| GPRC5D G protein-coupled receptor class C group 5 member D |
1 | 1 | Binding agent | Talquetamab |
| HAVCR2 Hepatitis A virus cellular receptor 2 |
1 | 0 | Inhibitor | Cobolimab |
| HCK HCK proto-oncogene, Src family tyrosine kinase |
1 | 0 | Inhibitor | Bosutinib |
| HCN4 Hyperpolarization activated cyclic nucleotide gated potassium channel 4 |
1 | 1 | Blocker | Ivabradine |
| HRH2 Histamine receptor H2 |
1 | 1 | Antagonist | Famotidine |
| HRH3 Histamine receptor H3 |
1 | 1 | Inverse agonist | Pitolisant |
| HTR1D 5-hydroxytryptamine receptor 1D |
1 | 0 | Antagonist | Risperidone |
| ICOS Inducible T cell costimulator |
1 | 1 | Agonist | Feladilimab |
| IFNA2 Interferon alpha 2 |
1 | 0 | Exogenous gene | Nadofaragene Firadenovec |
| IGHE Immunoglobulin heavy constant epsilon |
1 | 1 | Inhibitor | Omalizumab |
| IL17RA Interleukin 17 receptor A |
1 | 1 | Antagonist | Brodalumab |
| IL1A Interleukin 1 alpha |
1 | 0 | Inhibitor | Lutikizumab |
| IL1R1 Interleukin 1 receptor type 1 |
1 | 1 | Antagonist | Anakinra |
| IL31RA Interleukin 31 receptor A |
1 | 1 | Inhibitor | Nemolizumab |
| IL33 Interleukin 33 |
1 | 0 | Inhibitor | Itepekimab |
| IL5RA Interleukin 5 receptor subunit alpha |
1 | 1 | Inhibitor | Benralizumab |
| IMPA1 Inositol monophosphatase 1 |
1 | 0 | Inhibitor | Lithium Carbonate |
| IRAK1 Interleukin 1 receptor associated kinase 1 |
1 | 0 | Inhibitor | Pacritinib |
| ITGB6 Integrin subunit beta 6 |
1 | 0 | Binding agent | Sigvotatug Vedotin |
| KCNN4 Potassium calcium-activated channel subfamily N member 4 |
1 | 1 | Blocker | Senicapoc |
| KDM1A Lysine demethylase 1A |
1 | 0 | Inhibitor | Bomedemstat |
| KLKB1 Kallikrein B1 |
1 | 1 | Inhibitor | Berotralstat |
| KLRC1 Killer cell lectin like receptor C1 |
1 | 1 | Inhibitor | Monalizumab |
| LCK LCK proto-oncogene, Src family tyrosine kinase |
1 | 0 | Inhibitor | Pazopanib |
| LDHA Lactate dehydrogenase A |
1 | 0 | Rnai inhibitor | Dcr-Phxc |
| LIPF Lipase F, gastric type |
1 | 0 | Inhibitor | Orlistat |
| LRRC32 Leucine rich repeat containing 32 |
1 | 0 | Binding | Livmoniplimab |
| LYN LYN proto-oncogene, Src family tyrosine kinase |
1 | 1 | Inhibitor | Bosutinib |
| MAPK1 Mitogen-activated protein kinase 1 |
1 | 1 | Inhibitor | Ulixertinib |
| MAPK11 Mitogen-activated protein kinase 11 |
1 | 0 | Inhibitor | Regorafenib |
| MAPK14 Mitogen-activated protein kinase 14 |
1 | 1 | Inhibitor | Neflamapimod |
| MAPK3 Mitogen-activated protein kinase 3 |
1 | 1 | Inhibitor | Ulixertinib |
| MC4R Melanocortin 4 receptor |
1 | 1 | Agonist | Setmelanotide |
| MEN1 Menin 1 |
1 | 0 | Inhibitor | Revumenib |
| MGAM Maltase-glucoamylase |
1 | 1 | Inhibitor | Acarbose |
| MIF Macrophage migration inhibitory factor |
1 | 0 | Inhibitor | Iguratimod |
| MMP1 Matrix metallopeptidase 1 |
1 | 0 | Inhibitor | Doxycycline |
| MMP13 Matrix metallopeptidase 13 |
1 | 0 | Inhibitor | Doxycycline |
| MMP7 Matrix metallopeptidase 7 |
1 | 1 | Inhibitor | Doxycycline |
| MMP8 Matrix metallopeptidase 8 |
1 | 1 | Inhibitor | Doxycycline |
| MMP9 Matrix metallopeptidase 9 |
1 | 1 | Inhibitor | Andecaliximab |
| MSLN Mesothelin |
1 | 0 | Binding agent | Anetumab Ravtansine |
| MST1R Macrophage stimulating 1 receptor |
1 | 0 | Inhibitor | Crizotinib |
| MSTN Myostatin |
1 | 0 | Inhibitor | Apitegromab |
| MUC16 Mucin 16, cell surface associated |
1 | 0 | Other | Oregovomab |
| NECTIN4 Nectin cell adhesion molecule 4 |
1 | 1 | Binding agent | Enfortumab Vedotin |
| NFE2L2 NFE2 like bZIP transcription factor 2 |
1 | 1 | Activator | Omaveloxolone |
| NOD2 Nucleotide binding oligomerization domain containing 2 |
1 | 0 | Other | Mifamurtide |
| NPC1L1 NPC1 like intracellular cholesterol transporter 1 |
1 | 1 | Inhibitor | Ezetimibe |
| NQO1 NAD(P)H quinone dehydrogenase 1 |
1 | 0 | Modulator | Vatiquinone |
| NR1H4 Nuclear receptor subfamily 1 group H member 4 |
1 | 0 | Agonist | Ursodeoxycholic Acid |
| NT5E 5'-nucleotidase ecto |
1 | 1 | Inhibitor | Oleclumab |
| P2RX3 Purinergic receptor P2X 3 |
1 | 1 | Antagonist | Camlipixant |
| PGA5 Pepsinogen A5 |
1 | 0 | Inhibitor | Sucralfate |
| PLAU Plasminogen activator, urokinase |
1 | 0 | Exogenous protein | Urokinase |
| PLG Plasminogen |
1 | 1 | Inhibitor | Tranexamic Acid |
| PLK1 Polo like kinase 1 |
1 | 1 | Inhibitor | Onvansertib |
| PLK4 Polo like kinase 4 |
1 | 0 | Inhibitor | CFI-400945 |
| PMEL Premelanosome protein |
1 | 0 | Binding agent | Tebentafusp |
| PNLIP Pancreatic lipase |
1 | 1 | Inhibitor | Orlistat |
| PPP2CA Protein phosphatase 2 catalytic subunit alpha |
1 | 0 | Inhibitor | LB-100 |
| PPP2CB Protein phosphatase 2 catalytic subunit beta |
1 | 0 | Inhibitor | LB-100 |
| PPP3CA Protein phosphatase 3 catalytic subunit alpha |
1 | 0 | Inhibitor | Voclosporin |
| PPP5C Protein phosphatase 5 catalytic subunit |
1 | 0 | Inhibitor | LB-100 |
| PRSS1 Serine protease 1 |
1 | 0 | Inhibition | Nafamostat Mesylate |
| PTAFR Platelet activating factor receptor |
1 | 1 | Antagonist | Rupatadine |
| PTGER3 Prostaglandin E receptor 3 |
1 | 1 | Agonist | Misoprostol |
| PTGER4 Prostaglandin E receptor 4 |
1 | 0 | Antagonist | Vorbipiprant |
| PTK2B Protein tyrosine kinase 2 beta |
1 | 0 | Inhibitor | Defactinib |
| PTK6 Protein tyrosine kinase 6 |
1 | 0 | Inhibitor | Vandetanib |
| PTPN11 Protein tyrosine phosphatase non-receptor type 11 |
1 | 1 | Inhibitor | TNO155 |
| SELP Selectin P |
1 | 1 | Blocker | Crizanlizumab |
| SIGMAR1 Sigma non-opioid intracellular receptor 1 |
1 | 1 | Agonist | Dextromethorphan |
| SLAMF7 SLAM family member 7 |
1 | 1 | Inhibitor | Elotuzumab |
| SLC10A1 Solute carrier family 10 member 1 |
1 | 1 | Inhibitor | Bulevirtide |
| SLC22A11 Solute carrier family 22 member 11 |
1 | 0 | Inhibitor | Probenecid |
| SLC22A12 Solute carrier family 22 member 12 |
1 | 1 | Inhibitor | Dotinurad |
| SLC22A6 Solute carrier family 22 member 6 |
1 | 1 | Inhibitor | Probenecid |
| SLC22A8 Solute carrier family 22 member 8 |
1 | 0 | Inhibitor | Probenecid |
| SLC29A1 Solute carrier family 29 member 1 (Augustine blood group) |
1 | 1 | Inhibitor | Dipyridamole |
| SLC5A1 Solute carrier family 5 member 1 |
1 | 1 | Inhibitor | Sotagliflozin |
| SLC6A9 Solute carrier family 6 member 9 |
1 | 1 | Inhibitor | Bitopertin |
| SLC9A3 Solute carrier family 9 member A3 |
1 | 1 | Inhibitor | Tenapanor |
| SNCA Synuclein alpha |
1 | 1 | Binding agent | Prasinezumab |
| SOD1 Superoxide dismutase 1 |
1 | 0 | Antisense inhibitor | Tofersen |
| STAT3 Signal transducer and activator of transcription 3 |
1 | 0 | Antisense inhibitor | Danvatirsen |
| TAAR1 Trace amine associated receptor 1 |
1 | 1 | Agonist | Ulotaront |
| TACR3 Tachykinin receptor 3 |
1 | 1 | Antagonist | Fezolinetant |
| TERT Telomerase reverse transcriptase |
1 | 0 | Inhibitor | Imetelstat sodium |
| TGFBR1 Transforming growth factor beta receptor 1 |
1 | 1 | Inhibitor | Galunisertib |
| TLR8 Toll like receptor 8 |
1 | 0 | Antagonist | Enpatoran |
| TNFRSF13C TNF receptor superfamily member 13C |
1 | 1 | Binding agent | Ianalumab |
| TNFRSF8 TNF receptor superfamily member 8 |
1 | 1 | Binding agent | Brentuximab Vedotin |
| TNFRSF9 TNF receptor superfamily member 9 |
1 | 1 | Agonist | Utomilumab |
| TNFSF11 TNF superfamily member 11 |
1 | 0 | Inhibitor | Denosumab |
| TNFSF4 TNF superfamily member 4 |
1 | 0 | Inhibitor | Amlitelimab |
| TPO Thyroid peroxidase |
1 | 1 | Inhibitor | Methimazole |
| TPSAB1 Tryptase alpha/beta 1 |
1 | 0 | Inhibition | Nafamostat Mesylate |
| TRAF3IP2 TRAF3 interacting protein 2 |
1 | 0 | Inhibitor | Iguratimod |
| TSLP Thymic stromal lymphopoietin |
1 | 0 | Inhibitor | Tezepelumab |
| TXNRD1 Thioredoxin reductase 1 |
1 | 0 | Inhibitor | Arsenic Trioxide |
| VEGFB Vascular endothelial growth factor B |
1 | 0 | Inhibitor | Conbercept |
| VEGFC Vascular endothelial growth factor C |
1 | 0 | Inhibitor | Conbercept |
| VKORC1 Vitamin K epoxide reductase complex subunit 1 |
1 | 1 | Inhibitor | Warfarin |
| VWF Von Willebrand factor |
1 | 0 | Exogenous protein | Vonicog Alfa |
| XPO1 Exportin 1 |
1 | 1 | Inhibitor | Selinexor |
A medicine is matched to ChEMBL when ChEMBL's name for it, or a synonym ChEMBL itself curates, is the same molecule as ours, and to the Guide to Pharmacology by ChEMBL ID or exact name; close spellings are never accepted. Combination products are not matched. The Guide to Pharmacology adds a medicine to a target only when that protein is its primary target.
Mechanisms and targets are ChEMBL's curated records as published in the Open Targets Platform, checked against the IUPHAR/BPS Guide to PHARMACOLOGY. The data on this page and in its download is shared under the same share-alike terms (CC BY-SA, and ODbL for the Guide to Pharmacology database).
A job re-reads both sources every 30 days and keeps the previous version if a refresh fails or returns far fewer medicines. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
